RESEARCH

Life-threatening bronchiolitis related to electronic cigarette use in a Canadian youth

Simon T. Landman MBBS, Inderdeep Dhaliwal MSc(HQ) MD, Constance A. Mackenzie MD MSc, Tereza Martinu MD MHS, Andrew Steel MBBS, Karen J. Bosma MD


ABSTRACT

BACKGROUND: Although electronic cigarettes (e-cigarettes) were initially marketed as a potential smoking-cessation aid and a safer alternative to smoking, the long-term health effect of e-cigarette use (“vaping”) is unknown. Vaping e-liquids expose the user to several potentially harmful chemicals, including diacetyl, a flavouring compound known to cause bronchiolitis obliterans with inhalational exposure (“popcorn worker’s lung”).

CASE DESCRIPTION: We report the case of a 17-year-old male who presented with intractable cough, progressive dyspnea and malaise after vaping flavoured e-liquids and tetrahydrocannabinol intensively. Initial physical examination showed fever, tachycardia, hypoxemia, and bibasilar inspiratory crackles on lung auscultation. Computed tomography of the chest showed diffuse centrilobular “tree-in-bud” nodularity, consistent with acute bronchiolitis. Multiple cultures, including from 2 bronchoalveolar lavage samples, and biopsy stains, were negative for infection. He required intubation, invasive mechanical ventilation and venovenous extracorporeal membrane oxygenation (ECMO) for refractory hypercapnia. The patient’s condition improved with high-dose corticosteroids. He was weaned off ECMO and mechanical ventilation, and discharged home after 47 days in hospital. Several months after hospital discharge, his exercise tolerance remained limited and pulmonary function tests showed persistent, fixed airflow obstruction with gas trapping. The patient’s clinical picture was suggestive of possible bronchiolitis obliterans, thought to be secondary to inhalation of flavouring agents in the e-liquids, although the exact mechanism of injury and causative agent are unknown.

INTERPRETATION: This case of severe acute bronchiolitis, causing near-fatal hypercapnic respiratory failure and chronic airflow obstruction in a previously healthy Canadian youth, may represent vaping-associated bronchiolitis obliterans. This novel pattern of pulmonary disease associated with vaping appears distinct from the type of alveolar injury predominantly reported in the recent outbreak of cases of vaping-associated pulmonary illness in the United States, underscoring the need for further research into all potentially toxic components of e-liquids and tighter regulation of e-cigarettes.

Electronic cigarettes (e-cigarettes) are the most commonly used nicotine products among Canadian youth; a 2017 study estimated that 272 000 Canadians aged 15 to 24 years had used e-cigarettes in the last 30 days. First available in China in 2004 and in the United States in 2006, e-cigarettes are battery-powered devices that aerosolize various substances for inhalation, including nicotine, tetrahydrocannabinol (THC), cannabidiol and flavouring agents that may contain diacetyl, a compound known to cause pulmonary toxicity. Since its introduction to the North American market, use of e-cigarettes, or “vaping,” has continued to rise. Although use of this heavily marketed device is rapidly growing and becoming commonplace in Canada — particularly among youth — the impact of e-cigarettes on health is poorly understood. In recent years, several patterns of adverse reactions to vaping have been reported, including hypersensitivity pneumonitis, diffuse alveolar hemorrhage, organizing pneumonia, acute eosinophilic pneumonia and lipid pneumonia. Most recently, a cluster of 53 cases in the US was described as having hypoxemia and bilateral ground-glass opacities, consistent with a diffuse alveolar damage pattern of lung injury. As of Nov. 13, 2019, 2172 cases of “e-cigarette, or...
vaping, product use-associated lung injury” (EVALI) have been reported to the Centers for Disease Control and Prevention (CDC) in the US, with 42 confirmed deaths.21 The specific compound(s) or ingredient(s) causing lung injury is still under investigation, but vitamin E acetate has been identified in the bronchoalveolar lavage fluid samples from 29 patients with EVALI.23 Although inhalation of diacetyl is known to cause flavouring-related lung disease in factory workers (bronchiolitis obliterans, or “popcorn worker’s lung”), to date, there have been no reported cases in the medical literature of bronchiolitis obliterans from vaping.

We present a case of severe acute bronchiolitis associated with vaping, causing near-fatal hypercapnic respiratory failure requiring intubation and extracorporeal membrane oxygenation (ECMO) in a 17-year-old male. Several months after resolution of the acute critical illness, this previously healthy youth displayed persistent, fixed airflow obstruction, which may represent bronchiolitis obliterans. This novel disease pattern of airway injury associated with vaping leading to chronic obstruction appears to be distinct from the alveolar injury characterizing the EVALI cases recently reported in the US, and the 7 confirmed or probable cases in Canada,24,25 highlighting the need for further research and regulation of e-cigarettes.

Methods

Case description
All 6 coauthors were involved in the clinical care of this patient. The information included in this report was garnered from direct communication, medical records and review of imaging and pathology.

Literature review
With the help of a medical librarian, we conducted a comprehensive literature search of the MEDLINE and Embase electronic databases, using the OvidSP search interface, from inception to Oct. 30, 2019. No language restrictions were applied. A sensitive search strategy was used to identify relevant case reports and case series using a combination of subject headings, phrases and keywords (Appendices 1 and 2, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.191402/-/DC1). The reference lists of identified case reports and an Internet search for other related literature were pH 7.34, PCO2 47 mm Hg and PO2 78 mm Hg. One day after intubation, the patient underwent bronchoscopy that showed bilateral frothy, mucopurulent secretions but no organisms on staining or culture of bronchoalveolar lavage. Antibiotics were broadened to piperacillin–tazobactam and amphotericin B, and he was transferred to a tertiary care intensive care unit (ICU) on day 8 of hospital admission.

On arrival to the tertiary care ICU, the patient’s Pao2 was 289 mm Hg on Fio2 1.0 (PaO2/FiO2 289), PCO2 was 109 mm Hg and pH was 7.12. A repeat bronchoscopy was done and again showed mucopurulent secretions bilaterally. Repeat microbiological investigations were negative, including repeat bronchoalveolar lavage bacterial and fungal cultures, acid-fast bacilli, galactomannan, Legionella, respiratory viral panel, and Pneumocystis jiroveci and blood cultures. Investigations for Q fever, viral hepatitis, HIV serology, and vasculitis, including antinuclear antibodies,
extractable nuclear antigen and antineutrophil cytoplasmic antibody, were also negative. The cell differential from bronchoalveolar lavage was 83% neutrophils. Transbronchial biopsies sampling 75–100 alveoli showed nonspecific acute inflammation and reactive changes, although there were no airway fragments present for comment (Figure 3). Staining for lipoid pneumonia was not completed. Iatrogenic pneumothorax developed in the patient, and he required a right-sided surgical chest tube.

Table 1: Patterns of disease shown in case reports of vaping-associated pulmonary illnesses: an overview of the medical literature up to Oct. 30, 2019*

<table>
<thead>
<tr>
<th>Type of lung injury or predominant disease pattern</th>
<th>No. of cases</th>
<th>Age and sex</th>
<th>Associated imaging findings</th>
<th>Level of care required</th>
</tr>
</thead>
<tbody>
<tr>
<td>Organizing pneumonia15–13,26</td>
<td>12</td>
<td>64M, 40F, 54M, 22M, 20M, 21M, 28M, 19M, 28M, 38M, 35M, 39M</td>
<td>1 patchy infiltrates, 11 diffuse GGO, 1 tree in bud, 1 pneumothorax with bilateral central opacities, bilateral reticulonodular opacities with subpleural sparing</td>
<td>7 hospital ward, 2 ICU, 3 unknown</td>
</tr>
<tr>
<td>Acute fibrinous pneumonitis with organization26</td>
<td>11‡</td>
<td>44M, 42M, 51M, 25M, 21M, 34F, 28M, 54F, 67M, 19M, 40M</td>
<td>5 diffuse GGO, 2 bilateral centrilobular GGO, 1 perihilar GGO, 1 tree in bud, 1 diffuse bronchocentric micronodular GGO, 1 diffuse bilateral opacities</td>
<td>11 unknown</td>
</tr>
<tr>
<td>Lipoid pneumonia17–21</td>
<td>10</td>
<td>42F, “young” F, 35F, 31F, 20§, 23§, 23§, 25§, 29§, 47§</td>
<td>8 diffuse GGO, 3 “crazy paving,” 1 consolidation, 1 basilar GGO</td>
<td>6 hospital ward, 4 ICU</td>
</tr>
<tr>
<td>Acute alveolitis or diffuse alveolar damage23,33</td>
<td>8¶</td>
<td>46M, 33M, 35M, 61M, 47F, 21M, 34F, 28M</td>
<td>6 bilateral diffuse GGO, 1 traction bronchiectasis</td>
<td>1 hospital ward, 6 ICU, 1 unknown</td>
</tr>
<tr>
<td>Pneumomediastinum or pneumothorax5–33</td>
<td>6</td>
<td>17M, 16M, 21M, 15M, 16M, 18M</td>
<td>2 pneumomediastinum, 1 tension pneumothorax, 3 nontension pneumothorax</td>
<td>6 hospital ward</td>
</tr>
<tr>
<td>Hypersensitivity pneumonitis5–8</td>
<td>4</td>
<td>73F, 16F, 23M, 18F</td>
<td>2 diffuse GGO, 2 septal thickening, 1 traction bronchiectasis, 1 honeycombing, 1 diffuse nodules</td>
<td>2 hospital ward, 1 ICU with ECMO, 1 ICU without ECMO</td>
</tr>
<tr>
<td>Granulomatous disease34,35</td>
<td>2</td>
<td>43F, 34F</td>
<td>2 bilateral nodules</td>
<td>2 hospital ward</td>
</tr>
<tr>
<td>Eosinophilic pneumonia5,16</td>
<td>2</td>
<td>18F, 20M</td>
<td>2 diffuse GGO, 1 airspace disease, 1 coalescing nodules</td>
<td>1 ICU, 1 hospital ward</td>
</tr>
<tr>
<td>Status asthmaticus16</td>
<td>2</td>
<td>16M, 14F</td>
<td>2 pneumomediastinum</td>
<td>2 ICU with ECMO</td>
</tr>
<tr>
<td>Bronchitis27–38</td>
<td>2</td>
<td>43M, 56F</td>
<td>1 no acute abnormality, 1 diffuse GGO, 1 “crazy paving”</td>
<td>1 outpatient, 1 hospital ward</td>
</tr>
<tr>
<td>Inhalation injury20,40</td>
<td>2</td>
<td>35F, 60M</td>
<td>1 nodular infiltrates, 1 mediastinal adenopathy, 1 bilateral GGO</td>
<td>1 ICU with ECMO, 1 hospital ward</td>
</tr>
<tr>
<td>Respiratory bronchiolitis–associated interstitial lung disease41</td>
<td>1</td>
<td>33M</td>
<td>Tree in bud</td>
<td>Hospital ward</td>
</tr>
<tr>
<td>Diffuse alveolar hemorrhage9</td>
<td>1</td>
<td>33M</td>
<td>Diffuse GGO</td>
<td>ICU</td>
</tr>
<tr>
<td>Hypereosinophilia with eosinophilic asthma42</td>
<td>1</td>
<td>18F</td>
<td>NA</td>
<td>Outpatient</td>
</tr>
<tr>
<td>Transient nodules in lung and liver43</td>
<td>1</td>
<td>45F</td>
<td>Multiple pulmonary and hepatic nodules</td>
<td>Hospital ward</td>
</tr>
<tr>
<td>Pleural effusion64</td>
<td>1</td>
<td>63M</td>
<td>Left-sided pleural effusion</td>
<td>Hospital ward</td>
</tr>
<tr>
<td>Severe persistent airflow obstruction in a long-standing smoker15,44</td>
<td>1</td>
<td>45M</td>
<td>Patchy GGO, mosaic attenuation</td>
<td>Outpatient</td>
</tr>
<tr>
<td>Upper airway damage46</td>
<td>1</td>
<td>30M</td>
<td>Moderate uvulitis and edema of the paratracheal musculature</td>
<td>ICU</td>
</tr>
</tbody>
</table>

Note: ECMO = extracorporeal membrane oxygenation, F = female, GGO = ground-glass opacities, ICU = intensive care unit, M = male, NA = not available.
**Case reports” refers to individual cases reported with pathology and imaging findings. Table 1 does not include the 53-person case cohort published by Layden et al.22 or 805 cases reported by Perrine et al.47
†Patient was a long-standing smoker. No baseline pulmonary function tests before illness.
1One death.
§Sex not defined
¶Two deaths.
On his ninth day of hospital admission, the patient required initiation of venovenous ECMO for severe refractory hypercapnia (maximum PCO₂ > 130 mm Hg), decreased lung compliance and difficulty ventilating. Methylprednisolone 100 mg daily administered intravenously was started. The patient’s condition stabilized on ECMO with normal blood gases. Trials of pressure-support ventilation were poorly tolerated as any reduction in sedation led to severe coughing spells. Similarly, ECMO support could be successfully reduced while the patient was under deep sedation, but ECMO weaning was not possible with lightening sedation, because of intractable coughing. A tracheostomy was inserted on day 16 of hospital admission (11 d after intubation) in case the endotracheal tube was stimulating the patient’s cough. His cough persisted after the tracheostomy and was resistant to nebulized and intravenous opioids, enteral codeine and gabapentin.

Given that the CT showed bronchiolitis, with a negative infectious workup, and that the patient had inhalational exposure to flavouring agents with a lack of response to moderate-dose corticosteroids, we were concerned that the process developing in his lungs could be bronchiolitis obliterans and therefore consulted
the regional lung transplant team. A surgical lung biopsy to confirm the diagnosis was considered but deemed too risky. The patient was transferred on ECMO to the lung transplant centre on day 21 of hospital admission for further evaluation.

Following transfer, the patient received intravenous methylprednisolone 1 g/d for 3 days, followed by a taper, with slow improvement over the following 2 weeks. He was weaned from ECMO and the ventilator, had his tracheostomy tube removed and was discharged home on a tapering dose of steroids after a total of 47 days in hospital.

The patient’s pulmonary physiology at 1-month follow-up showed severe obstruction with gas trapping, with a forced expiratory volume in 1 second (FEV1) of 1.28 L (31% predicted), forced vital capacity (FVC) of 2.56 L (52% predicted), FEV1/FVC of 50%, residual volume of 3.55 L (227% predicted), normal total lung capacity (6.02 L, 91% predicted) and low-normal diffusion capacity corrected for alveolar volume (99% predicted) (Figure 4). He was started on mometasone–formoterol 200/5 µg metered dose inhaler (MDI) 2 inhalations twice daily via spacer and tiotropium 2.5 mg mist inhaler 2 inhalations once daily, with salbutamol 100 µg MDI 2 puffs as needed for dyspnea.

The patient’s physiology improved slightly at 2 months after discharge, with a FEV1 of 44% predicted. Repeat chest CT showed improvement but not full resolution of the centrilobular nodules and new mild bronchial dilation within multiple basilar segments of both lower lobes, favoured to represent early developing bronchiectasis. He was instructed to restart prednisone at a dose of 0.5 mg/kg. At 3 months after discharge, his FEV1 was 55% predicted in keeping with persistent moderate airflow obstruction. He was clinically improving, albeit with limited activity tolerance. His prednisone dose was weaned to 15 mg daily. At 4 months, his FEV1 was slightly lower at 45% predicted, with no improvement postbronchodilator. He remained abstinent of e-cigarettes, marijuana and tobacco products.

This case was reported (S.T.L. and C.A.M.) to the Government of Canada through the consumer product incident report system on Aug. 20, 2019, under the Canada Consumer Product Safety Act. Additional case information was provided to the Tobacco and Vaping Compliance and Enforcement Program on Aug. 30, 2019, and follow-up communication was initiated by the authors (I.D. and S.T.L.) to Health Canada on Sept. 3, 2019. This case remains under investigation.

Figure 3: Histological sections of a transbronchial biopsy of the right lower lobe on day 8 of hospital admission at low (panel A, original magnification x 2), medium (panel B, original magnification x 4), high (panel C, original magnification x 10) and highest magnification (panel D, original magnification x 20) (hematoxylin and eosin stain). There is mild interstitial septal thickening secondary to acute inflammatory cells in the septi and type 2 pneumocyte hyperplasia (panel C). The airspaces are distended by a mixture of fibrin balls, neutrophils, macrophages and myofibroblast proliferation, with incorporation of myofibroblasts into the septi (panel D). These findings represent nonspecific acute inflammation and reactive changes in the airspaces. No bronchial mucosa is present for evaluation. The etiology of the findings is not identified. No infectious organisms are identified. Vasculitis and granulomatous inflammation is not identified. Hyaline membranes are not identified. Note the absence of viral cytopathic changes and paucity of foamy macrophages.
Literature review
Our search strategy identified 1442 records, of which 118 were case reports. After removal of duplicates, 83 records were reviewed; 37 did not meet our eligibility criteria, leaving 46 studies to be included in our qualitative synthesis (Figure 5). Published case reports of vaping-associated pulmonary disease date back to 2012, with an increase in reported cases over the last 3 years (Figure 6). From 2012 to Aug. 30, 2019 (before publication of the CDC investigation), there were 30 publications identifying a diverse array of vaping-associated pulmonary insults, with varying imaging and pathological findings, but no reported deaths (Table 1). From Sept. 1 to Oct. 30, 2019, an additional 13 publications were identified through our search strategy (Table 1).

Interpretation
This case of life-threatening acute bronchiolitis posed a diagnostic and therapeutic challenge. Given the patient’s intense vaping exposure to flavoured e-liquid and negative workup for other causes of bronchiolitis, we suspected that bronchiolitis obliterans might have been developing in this patient as in microwave-popcorn factory workers exposed to occupational inhalation of diacetyl. We referred him to a lung transplant centre for further evaluation and reported the case to authorities (Government of Canada’s consumer product incident report system) as an adverse reaction to a consumer product, e-cigarettes. Subsequently, media reports brought to light an outbreak of cases of hypoxemic pulmonary illness related to vaping, with a large proportion reporting use of THC. Concerned that this case might be similar, we reported it to Health Canada for further investigation. This index case highlights the need for clinicians and the public to be aware of the varying presentations of vaping-related illness and the potential acute and chronic effects of vaping, as well as the need for further research into the safety and toxicity of e-liquid compounds, and tighter regulation of e-cigarettes in Canada.

This patient had severe, acute bronchiolitis, possibly related to inhalational injury from vaping, with several features suggestive of subsequent early bronchiolitis obliterans. On arrival in our tertiary care ICU, this intubated patient had severe airflow obstruction with refractory hypercapnia requiring rescue therapy with ECMO, and a CT scan showing a tree-in-bud pattern. “Tree in bud” describes small centrilobular, well-defined nodules of soft-tissue attenuation connected to linear branching opacities. These nodules can represent bronchiolar inflammation and peribronchial fibrosis, and suggest small airways pathology. Diffuse tree-in-bud nodularity is most commonly associated with bacterial or viral infections, but can also be found with aspiration, posttransplant and inhalational exposure to toxins. For our patient, other infectious or inflammatory etiologies for the tree-in-bud opacities we observed were ruled out. Eng even bronchoalveolar lavage and transbronchial biopsies were obtained after initiation of antibiotics, stains of alveolar tissue would have shown evidence of viral, bacterial or fungal elements had they been present, whether such organisms grew in culture or not. Furthermore, his condition improved with high-dose intravenous steroids but not with wide-spectrum antimicrobials, making an infectious etiology less likely. Transbronchial biopsies ruled out diffuse alveolar damage, organizing pneumonia and hypersensitivity pneumonitis as potential etiologies for the centrilobular tree-in-bud pattern. This led us to consider toxic inhalational exposure from vaping as the cause of the acute bronchiolitis and, given the exposure to flavouring compounds in the e-liquids, we postulated that bronchiolitis obliterans could be developing in this patient.
Bronchiolitis obliterans refers to “the clinical syndrome associated with small airways injury caused by a spectrum of inhalational, infectious, and drug exposures, and also lung or hematopoietic cell transplantation.” It is “typically characterized by dyspnea, airflow limitation that is not reversible by inhaled bronchodilator, and a chest radiograph that shows normal or hyperinflated lungs.” Flavouring-associated lung disease is a form of bronchiolitis obliterans recognized as a rare but serious complication in workers exposed to flavouring chemicals such as diacetyl while working in the food and flavouring industry, including manufacturing of microwave popcorn, flavourings and diacetyl, as well as coffee-processing facilities. Lung-function abnormalities in these cases typically show irreversible airflow obstruction, with variable radiographic changes including mosaic attenuation, ground-glass opacities, bronchiectasis and centrilobular nodules. The time to diagnosis in these cases has often been delayed by many months after onset of symptoms, likely contributing to the variability in presentation. Our patient showed persistent airflow obstruction not reversible with bronchodilators and gas trapping on pulmonary function tests. Although CT did not show the classic mosaic attenuation indicative of gas trapping, CT images were taken during inhalation, not exhalation. Furthermore, the initial centrilobular nodules and later early mild bronchiectasis we observed could be in keeping with early bronchiolitis obliterans, even in the absence of mosaic attenuation. Unfortunately, our transbronchial biopsies did not contain airways, and surgical lung biopsy was deemed unsafe; therefore, we cannot confirm pathologically that this was bronchiolitis obliterans. Additionally, the exact causative agent(s) and mechanism of bronchial epithelial injury are unknown, though we speculate that vaping probably played a role given that no other possible cause was identified.

Following our reporting of this case to the Government of Canada as a vaping-related adverse event under the Canada Consumer Product Safety Act on Aug. 20, 2019, the CDC released its official health advisory statement on Aug. 30, 2019, regarding the multistate outbreak of severe pulmonary disease associated with use of e-cigarette products, most commonly, though not always, including use of THC. This report led us to re-examine our case and issue a follow-up report to Health Canada on Sept. 3, 2019. Similar to most cases reported to the CDC, our case involved a youth who vaped daily, used a variety of flavoured cartridges and reported use of THC products. Also similar to the most severe cases reported in the US, our patient required critical care and invasive mechanical ventilation, and his condition improved with administration of high-dose systemic corticosteroids. However, unlike in other cases, our patient had predominantly hypercapnic respiratory failure with severe obstructive physiology as the primary indication for ECMO, rather than diffuse alveolar damage and acute

---

**Figure 5:** Flow diagram showing selection of relevant published case studies.

**Figure 6:** Number of published case reports and case series on vaping-associated pulmonary disease, by year published.
respiratory distress syndrome. In keeping with this, CT showed a diffuse tree-in-bud pattern rather than the bilateral ground-glass opacities that characterize the surveillance case definition for the CDC investigation and Health Canada’s national outbreak case definition.24

To date, “tree in bud” is an uncommon pattern in vaping-related pulmonary disease. The current literature suggests that the most common imaging pattern is basilar-predominant consolidation and ground-glass opacity, often with areas of lobular or subpleural sparing,51 although previous case reports have described diverse imaging findings.8,9,11,19,20,34,39,42,51 Similarly, the pathologic findings can vary,13,26 although in the recent case series by Butt and colleagues,26 all cases showed 1 or more pattern or feature of acute lung injury, including acute fibrosing pneumonitis, diffuse alveolar damage, organizing pneumonia, interstitial edema, intra-alveolar fibrin and reactive type 2 pneumocyte hyperplasia. Additionally, airway-centred accumulation of foamy macrophages in peribronchiolar airspaces was universally present, along with vacuolization of the cytoplasm of hyperplastic type 2 pneumocytes. In our case, foamy macrophages were rare; although there was mild interstitial septal thickening and type 2 pneumocyte hyperplasia, pneumocyte vacuolization was not reported.

Our case, the EVALI cases reported in the US and Canada, and the cases of serious adverse reactions to vaping reported in the medical literature to date depict a variety of pathophysiological presentations and severity of disease. This heterogeneity may be from exposure to different causative agents within the e-cigarettes; the combination of agents reacting in vitro or in vivo to generate new compounds with increased toxicity;66 the dose, solubility or temperature of the inhaled agent; or inhalational techniques determining whether the compound is deposited in the airways or alveoli. Although the exact causative agent(s) and mechanisms of respiratory injury are unknown at this time, there is growing evidence that several compounds present in e-liquids may pose risk of harm when inhaled.

E-cigarettes are known to contain harmful substances, including nicotine, vitamin E acetate, volatile organic compounds, heavy metals, ultra-fine particles and carbonyl compounds.12,23,52,53,66,67 (Box 1). Of particular concern is the use of flavouring agents in e-liquids. There are more than 7700 e-liquid flavours across 460 brands.69 Although many of these flavours are “generally recognized as safe” under the US Federal Food, Drug, and Cosmetic Act, it is important to recognize that this applies only to ingestion;68 aerosolization of flavours safe for ingestion may produce adverse health effects that are yet undetermined.70

A key example of a flavouring agent that is safe for ingestion but not inhalation is diacetyl (2,3-butanedione). Diacetyl belongs to a class of organic compounds referred to as diketones and is known for its characteristic butter flavour.71 It is found naturally in some foods and used as a synthetic flavouring agent in butter, cocoa, caramel, coffee, dairy products and alcoholic beverages.71 Occupational diacetyl inhalation is associated with decline in respiratory function, obstructive lung disease and decreased FEV1,55 as well as bronchiolitis obliterans.57 Bronchiolitis obliterans from diacetyl exposure is also known as “popcorn worker’s lung” owing to its initial description in patient clusters of microwave-popcorn factory workers exposed to diacetyl-based flavouring agents.55–57 Diacetyl and another flavouring agent, 2,3-pentanedione, can alter gene expression pathways related to cilia and cytoskeletal processes in normal human bronchial epithelial cells,72 and cause epithelial cell injury and bronchiolitis obliterans in rodents.73,74 Although the mechanisms behind bronchiolitis obliterans remain incompletely understood, inhaled diacetyl influences human cellular matrix remodelling and may stimulate fibroproliferative changes in human airways.75

Diacetyl has been identified in e-liquids at levels higher than recommended safety limits, including in some products in which the packaging clearly stated that diacetyl was not an ingredient.79 One study found it in more than 60% of e-cigarette flavour samples analyzed,68 and another study showed that diacetyl is generated within e-liquids over time from another flavouring agent, acetoin.77 The chemical synthesis of diacetyl from acetoin is accelerated when nicotine is added to vaping fluid, with diacetyl concentrations increasing over time.77 Vaping fluid that is stored for a prolonged period could therefore accumulate high levels of diacetyl that, when vapourized, may increase risk for pulmonary toxicity. Our patient’s vaping liquid was not available for analysis, but similarly flavoured products have been shown to contain flavouring agents including diacetyl.88

Our patient also vaped THC, which has been identified as an exposure in most recent cases: among 86 patients in Illinois and Wisconsin, 87% reported vaping THC products.4 In the

<table>
<thead>
<tr>
<th>E-liquid component</th>
<th>Chemical or compound</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carrier solution</td>
<td>• Propylene glycol</td>
</tr>
<tr>
<td></td>
<td>• Vegetable glycerin</td>
</tr>
<tr>
<td>Flavourants</td>
<td>• Diacetyl</td>
</tr>
<tr>
<td></td>
<td>• 2,3-Pentanedione</td>
</tr>
<tr>
<td></td>
<td>• Acetoin</td>
</tr>
<tr>
<td>Additives</td>
<td>• Nicotine</td>
</tr>
<tr>
<td></td>
<td>• Tetrahydrocannabinol</td>
</tr>
<tr>
<td></td>
<td>• Cannabidiol</td>
</tr>
<tr>
<td></td>
<td>• Butane hash oil</td>
</tr>
<tr>
<td></td>
<td>• Other oil-rich additives</td>
</tr>
<tr>
<td>Adulterants</td>
<td>• Vitamin E acetate (tetrahydrocannabinol adulterant)</td>
</tr>
<tr>
<td>Aerosol emissions</td>
<td>• Carbonyls from heating propylene glycol and vegetable glycerin</td>
</tr>
<tr>
<td></td>
<td>• Particulates</td>
</tr>
<tr>
<td></td>
<td>• Trace metal elements</td>
</tr>
<tr>
<td></td>
<td>• Volatile organic compounds</td>
</tr>
<tr>
<td>Contaminants</td>
<td>• Bacterial endotoxins</td>
</tr>
<tr>
<td></td>
<td>• Fungal glucans</td>
</tr>
</tbody>
</table>
preliminary report published by Layden and colleagues.22 A total of 80% reported using THC products, 61% reported using nicotine products and 7% reported using cannabinoid products; 44% reported using both nicotine and THC products, while 37% reported using only THC products and 17% used only nicotine-containing products.22 Patients reported using numerous brands in a wide range of flavours, though details on the exact flavouring agents used were not provided. The investigation involves a wide variety of substances and e-cigarette products.

Although the CDC has identified vitamin E acetate as a chemical of concern in their investigation, evidence is not yet sufficient to rule out other chemicals still under investigation; there may be more than one cause, and it is not yet known whether other agents play a role in the outbreak.23 Likewise, we cannot pinpoint the causative agent(s) responsible for our patient’s pulmonary illness, as he vaped a variety of substances of which more than one may be a causative agent for harm.

E-cigarettes were first marketed in North America as a safer alternative to smoking traditional tobacco cigarettes and as a potential smoking-cessation aid. However, with heavy marketing, an enticing array of flavours and the potential to inhale drugs other than nicotine, vaping has become increasingly popular, particularly among youth. Until recently, reporting and surveillance mechanisms for adverse health effects related to e-cigarette use in Canada were limited. Following the CDC health advisory statement on Aug. 30, 2019 (https://emergency.cdc.gov/han/han00421.asp), Health Canada issued a warning on Sept. 4, 2019, regarding the potential risk of pulmonary illness associated with vaping.29 Simultaneously, the Public Health Agency of Canada alerted provincial and territorial public health officials to report possible cases in their jurisdictions.25

As of Nov. 12, 2019, there have been 2 confirmed cases of vaping-associated pulmonary illness in Quebec, 2 probable cases in New Brunswick and 3 probable cases in British Columbia.25 In addition to highlighting the need for improved surveillance, the Canadian Heart and Stroke Foundation is suggesting that the federal and provincial governments dedicate research funding to understanding the patterns of use and potential benefits of e-cigarettes as a smoking-cessation tool as well as their possible risks.78 The sale of nicotine-containing e-cigarette products to adults became legal in Canada in May 2018 through the Tobacco and Vaping Products Act. The recent outbreak of cases and deaths related to vaping has led the US government to propose moving to ban all flavoured e-cigarettes other than tobacco-flavoured products in the coming months,79 and Thailand, India and Brazil have moved to ban e-cigarettes completely. The Canadian Heart and Stroke Foundation is calling for a ban on the sale of e-liquid flavours that are attractive to youth, regulations to minimize the toxic additives in e-liquids, and raising the minimum age of purchase for both tobacco and e-cigarettes to 21 years of age.78 At this time, there are no proposed changes to the Tobacco and Vaping Products Act in Canada.

Limitations

The patient, his family and his health care team recognized the need to raise public awareness around this index case of vaping-related illness in Canada; however, this work has several limitations. The transbronchial biopsies did not include airway mucosa for evaluation, and because of the preparation method, no staining for lipid pneumonia could be done. The bronchoscopies and biopsies were performed after initiation of antibiotics. Although the patient’s severe hypercapnia predated the iatrogenic pneumothorax, the difficulty ventilating the patient may have been exacerbated by the pneumothorax. Finally, although a careful history of the products vaped was obtained, no vaping products were available for analysis. Regarding our literature review, we searched MEDLINE and Embase databases without restriction of language; however, we did not search biomedical databases originating in China, the country of origin for e-cigarettes.

Conclusion

This case of acute, life-threatening bronchiolitis resulting in fixed, chronic airflow obstruction in a previously healthy youth highlights the need for further research on the epidemiology of e-cigarette use, its addictive potential, and the short- and long-term risks and mechanisms of injury associated with vaping. Furthermore, there is urgent need for tighter regulation of the vaping industry, including marketing, ingredient disclosure, sale to youth, and testing of e-liquid components that may be “generally regarded as safe” for ingestion but may pose risk of serious harm when inhaled.

References


Competing interests: None declared.

Affiliations: Divisions of Respirology (Landman, Dhaliwal, Mackenzie, Bosma), Clinical Pharmacology and Toxicology (Mackenzie), and Critical Care Medicine (Bosma), Department of Medicine, Schulich School of Medicine & Dentistry, Western University, London, Ont.; Ontario, Manitoba and Nunavut Poison Centres (Mackenzie), The Hospital for Sick Children; Division of Respirology (Martinu), Department of Medicine, Toronto Lung Transplant Program, University Health Network; Interdepartmental Division of Critical Care Medicine (Steel), Department of Anesthesiology, Faculty of Medicine, University of Toronto, Toronto, Ont.

Contributors: Simon Landman and Karen Bosma drafted the original version. Inderdeep Dhaliwal, Constance Mackenzie, Tereza Martinu and Andrew Steel provided interpretation of data for the work and critical revision for intellectual content. All authors provided feedback on revisions, provided final approval of the version to be published and agree to be accountable for all aspects of the work.


Acknowledgements: The authors thank Ms. Alla lansavitchene, professional medical librarian, for her assistance with the literature searches and retrieving full-text articles; Dr. Keith Kwan, pulmonary pathologist, for his review of this case and providing pathology slides and interpretation; and Dr. lan Chan, chest radiologist, for reviewing and providing further interpretation of computed tomography images.

Accepted: Nov. 11, 2019
Correspondence to: Karen Bosma, Karen.J.Bosma@lhsc.on.ca